Bristol-Myers Squibb Company, Pfizer Inc. Drug Ups Bleeding in Heart Study

MUNICH, Sept 2 (Reuters) - Bristol-Myers Squibb and Pfizer's apixaban blood clot preventer raised rates of bleeding in a 6-month study but showed some encouraging signs of protecting at-risk heart patients, researchers said on Tuesday.